Skip to Content
Home > About Us > Research and Grants Administration > Results
The purpose of this study is to compare any good and bad effects patients with early stage non-small cell lung cancer that was surgically removed may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug).
The purpose of this research study is to look at lung cancer patients’ tumors that were removed by surgery for certain genetic changes, and to possibly offer these patients a treatment study with drugs that may specifically target tumors that have these genetic changes.
The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI®), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for patients with ALK-positive non-small cell lung cancer.
This study is for patients that have advanced non-small cell lung cancer and has two steps: the initial screening step where we will examine tumor tissue and the sub-study treatment step where patients will be assigned to a treatment sub-study that is chosen based on the screening results.
This trial is for patients who have already received the information on the results of the biomarker testing as part of the LUNGMAP screening trial. Patients eligible for this study have a tumor sample that did not have a biomarker that matches one of the treatment studies that are open or because you were not a candidate for a biomarker-matched treatment study. For this sub-study, patients will be assigned to treatment with either the usual treatment, which is the current standard of care drug (docetaxel, gemcitabine, pemetrexed [for non-squamous cell Non-small cell lung cancer only], or ramucirumab combined with docetaxel) or to the investigational therapy (ramucirumab combined with pembrolizumab).
This trial is for patients who have already received the information on the results of the biomarker testing as part of the LUNGMAP screening trial. Patients eligible for this study have a tumor sample that is LOH-positive (Loss of Heterozygosity, which is a genomic variation in the make-up of the cancer cells) or BRCA-positive (a mutation in either the BRCA1 or BRCA2 genes, which are tumor suppressor genes).
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO®), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer.
View Additional Section Content
For more information about our research program and IRB, please contact: